Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · Real-Time Price · USD
21.68
-1.73 (-7.39%)
At close: Apr 2, 2026, 4:00 PM EDT
21.74
+0.06 (0.28%)
After-hours: Apr 2, 2026, 7:49 PM EDT
Alto Neuroscience Employees
Alto Neuroscience had 68 employees as of December 31, 2025. The number of employees decreased by 8 or -10.53% compared to the previous year.
Employees
68
Change (1Y)
-8
Growth (1Y)
-10.53%
Revenue / Employee
n/a
Profits / Employee
-$929,971
Market Cap
692.58M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 68 | -8 | -10.53% |
| Dec 31, 2024 | 76 | 9 | 13.43% |
| Sep 30, 2024 | 88 | 27 | 44.26% |
| Jun 30, 2024 | 78 | 17 | 27.87% |
| Mar 31, 2024 | 67 | - | - |
| Sep 30, 2023 | 61 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| Replimune Group | 479 |
| Arvinas | 246 |
| Solid Biosciences | 121 |
| BridgeBio Oncology Therapeutics | 92 |
| Lexicon Pharmaceuticals | 81 |
| Design Therapeutics | 54 |
| Bright Minds Biosciences | 26 |
ANRO News
- 1 day ago - Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements - Business Wire
- 18 days ago - Alto Neuroscience Announces $120 Million Private Placement Financing - Business Wire
- 18 days ago - Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights - Business Wire
- 21 days ago - Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum - Business Wire
- 5 weeks ago - Alto Neuroscience Announces Participation in Upcoming Investor Conferences - Business Wire
- 7 weeks ago - Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia - Business Wire
- 2 months ago - Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment - Business Wire
- 2 months ago - Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression - Business Wire